Drugs / NUZ-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07410806 | Feb 2026 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUZ-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410806 ↗ |
| Route | Oral | “Drug: NUZ-001. Administration: Oral. Dose: Once per day.” NCT04297683 ↗ |